A Deepening Controversy in Alternative Medicine: How a Supplement Study Sparks Regulatory and Ethical Concerns
The world of health supplements and experimental treatments is often shrouded in both promise and controversy, but what happens when a researcher bypasses crucial regulatory steps? And this is the part most people miss—such oversights can put patients at serious, sometimes hidden risks. Recently, the spotlight has shone brightly on Dayan Goodenowe, founder of the Moose Jaw-based Dr. Goodenowe Restorative Health Center in Saskatchewan. The U.S. Food and Drug Administration (FDA) has formally criticized him, accusing his recent clinical trial of compromising patient safety.
On January 20th, the FDA issued a public warning letter directed at Goodenowe and his company, Prodrome Sciences USA, LLC. This company produces supplement pills and oils that claim to help prevent or even reverse degenerative diseases like ALS, Alzheimer’s, and Autism. The FDA’s concern stems from a study conducted between 2020 and 2021 involving 29 participants, aimed at testing the safety and tolerability of ProdromeNeuro in individuals with mild to moderate dementia.
This clinical trial, titled "Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons," was published in 2022 in the journal Frontiers in Cell and Developmental Biology. While the FDA’s warning highlights that the study endangered patient health, it’s notable that no participants are reported to have experienced adverse effects based on current information.
But here’s where it gets controversial—the FDA has revealed that Goodenowe failed to file an Investigational New Drug (IND) application before starting the trial. An IND is a critical document submitted to the FDA that provides essential safety data, including results from animal testing, details about the drug’s ingredients, and manufacturing protocols. This paperwork ensures that any experimental drug or supplement is introduced into human trials under strict safety standards.
By skipping this step, Goodenowe essentially conducted an unapproved human experiment, which raises serious ethical and legal questions. The FDA expressed alarm that this oversight jeopardizes the welfare of the trial participants and calls into question the integrity of the data collected. Furthermore, shortly after the warning was issued, the journal Frontiers flagged the published research with an "expression of concern," citing compliance issues with local legislation and ongoing investigations.
Industry and research ethics expert Janice Parente emphasizes the danger of such violations. She points out that when researchers neglect proper regulatory procedures, they inadvertently expose patients to unnecessary risks without their informed consent. "Patients assume that because health professionals are conducting the study, it’s all properly managed," she explains. Missing this fundamental step means that the researcher has taken regulatory control into their own hands, effectively self-regulating—an extremely risky practice.
Goodenowe, when approached for comment, attributed the oversight to a miscommunication, promising resolution soon, though he offered no specifics. Meanwhile, the incident hasn’t slowed his ambitious expansion plans. Over recent months, Goodenowe announced new ventures in China and Japan, including partnerships to distribute his products internationally.
This isn’t the first time Goodenowe’s work has attracted scrutiny. CBC investigations last year cast doubt on his claims of 100% success in halting ALS progression and questioned whether his programs truly delivered the promised results. Several ALS patients who paid thousands of dollars for his treatments reported continued deterioration, contradicting his assertions of successful outcomes. While Goodenowe admits there’s no scientific proof backing his claims, he promotes anecdotal testimonials as proof of effectiveness.
The regulatory backlash intensified after CBC’s reports, prompting investigations by provincial health authorities and law enforcement, as well as a defamation lawsuit from Goodenowe against CBC, claiming conspiracy and misinformation. The core issue remains: can a supplement or treatment claiming to influence complex, life-altering diseases be legitimately marketed without rigorous, regulatory-approved testing?
In his own studies, Goodenowe reported positive outcomes—improved mobility and cognitive functions—in users of ProdromeNeuro, suggesting a breakthrough in Alzheimer’s research. He claims his supplement, based on naturally occurring compounds from shark liver oil, doesn’t require FDA approval because it's classified as a dietary supplement. However, the FDA disagrees, asserting that such products used for disease treatment are classified as drugs and require proper approval.
Following the regulatory findings, Goodenowe took some steps towards compliance by hiring consultants and promising internal reviews. Yet, critics like research ethics experts argue that neglecting to submit the necessary applications isn’t just a procedural slip but a legal breach.
Adding fuel to the fire, prominent academics such as Timothy Caulfield warn that such regulatory lapses should be an urgent red flag for authorities nationwide, especially considering Goodenowe’s operation is unregulated, outside standard medical oversight, and run by someone who isn’t a licensed physician. His previous claims about extensive FDA experience seem at odds with the current regulatory failures.
Despite these ongoing issues, Goodenowe’s push into international markets continues. Announcements reveal initiatives to build health centers, establish a national health network in China, and produce supplements in Canada. However, Health Canada has clarified that it hasn’t yet approved or received applications for these products, leaving their regulation and safety in a gray area.
So, the question remains: How far should we trust bold claims from unconventional health entrepreneurs, especially when regulatory bypasses come to light? Is innovation worth the risk when patient safety might be compromised? Share your thoughts below—do you believe in the potential of these supplements, or do you see this as a cautionary tale about unchecked research and marketing practices?
